Cellectar reports FY2023 net loss $38M; plans iopofosine NDA submission H2 2024

Cellectar Biosciences, Inc.

Net loss $38.0M ($3.11 per share) vs $28.6M ($4.05) in prior year.
Cash $9.6M at Dec 31, 2023; plus $44.1M from Jan 2024 warrant exercise funds into Q4 2024.
CLOVER WaM study met primary endpoint: MRR 61%, ORR 75.6%, 7.3% CR in refractory WM.
R&D expense $28.2M, up 47% YoY, driven by manufacturing for trials and commercial readiness.
Positive topline data announced; NDA submission planned H2 2024 with request for accelerated approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cellectar Biosciences, Inc. reported financial results for year ended December 31, 2023.

Period: year ended December 31, 2023
Result: reported results

Exact text from the filing

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-039341

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.